CFRA upgrades Amgen to 'buy'

CFRA upgrades Amgen to 'buy'

An analyst from CFRA upgraded Amgen (NASDAQ: AMGN ) from 'hold' to 'buy' .

Prior to this rating, Amgen had 10 buy ratings, 12 hold ratings, and 4 sell ratings.

For consensus analyst estimates and price targets on Amgen, click here. For more news on Amgen, click here.

Amgen's stock price closed at $230.70. They are up 5.51% in the last month and down -0.30% in the last 12 months.

According to Investing Pro, Amgen's fair value is $285.05, an upside of 16.48%. Amgen's fair value comes with a low degree of uncertainty, according to InvestingPro.

Check out Amgen's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or


Related Articles